Syndax Pharmaceuticals
Markets targeted therapies for acute leukemias and chronic graft-versus-host disease.
Something off on this page? Send us feedback.
Profile
Markets Revuforj for genetically defined relapsed or refractory acute leukemias and shares U.S. economics on Niktimvo for chronic graft-versus-host disease with Incyte. Revenue comes from direct Revuforj sales and Niktimvo collaboration income, while broader-use trials and two early candidates extend the oncology pipeline.
Commercializes two FDA-approved medicines while testing them in earlier treatment settings and additional diseases. Revuforj (revumenib), an oral menin inhibitor, treats relapsed or refractory acute leukemia with a KMT2A translocation and certain acute myeloid leukemia with an NPM1 mutation. Niktimvo (axatilimab-csfr), a CSF-1R-blocking antibody, treats chronic graft-versus-host disease after prior systemic therapies.
Manages Revuforj sales through internal resources and third parties. Incyte leads Niktimvo commercialization; the partners share U.S. profit and loss equally, while Incyte holds commercial rights elsewhere. Pipeline work includes broader uses for both medicines plus SNDX-4321 and SNDX-62122.
Operates as one segment from New York. Revenue is concentrated in these medicines; manufacturing is outsourced, and execution depends on regulators, reimbursement, licensed intellectual property, contract manufacturers, and the Incyte collaboration.
Company facts
Key statistics
Year to date −8.3% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 21, 2026 | UBS | Reiterate | Buy | $38 | $33 |
| Aug 5, 2026 | H.C. Wainwright | Target | $40 | $38 | |
| Jun 12, 2026 | Guggenheim | Target | $31 | ||
| Jun 3, 2026 | H.C. Wainwright | Target | $33 | $40 | |
| May 4, 2026 | Stifel Nicolaus | Target | $45 | $46 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.45 | −$0.55 | −22.9% | $79.4M | $72.8M | −8.3% | +4.40% |
| Apr 30, 2026Q1 FY26 | −$0.59 | −$0.48 | +18.6% | $69.8M | $64.9M | −7.0% | −10.83% |
| Feb 26, 2026Q4 FY25 | −$0.58 | −$0.78 | −33.6% | $64.3M | $68.7M | +6.9% | +5.03% |
| Nov 3, 2025Q3 FY25 | −$0.74 | −$0.70 | +5.4% | $63.3M | $45.9M | −27.6% | +11.56% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.0M | $38.0M | $45.9M | $68.5M | $64.9M | $72.8M | |
| Gross profit | $19.2M | $36.7M | $43.8M | $70.1M | $62.2M | $69.6M | |
| Operating income | −$83.8M | −$69.4M | −$57.4M | −$62.5M | −$34.2M | −$40.0M | |
| Net income | −$84.8M | −$71.8M | −$60.7M | −$68.0M | −$42.7M | −$49.4M | |
| Diluted EPS | −$0.99 | −$0.83 | −$0.70 | −$0.78 | −$0.49 | −$0.55 | |
| Gross margin | 95.6% | 96.6% | 95.4% | 102.3% | 95.9% | 95.6% | |
| Operating margin | -417.9% | -182.7% | -125.2% | -91.3% | -52.7% | -54.9% |
Fiscal years (4-quarter sums)FY21 $139.7M · FY22 $0 · FY23 $0 · FY24 $23.7M · FY25 $172.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $547.9M · Total debt $589.4M · Total assets $703.7M · Shareholders' equity $15.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 88.61M · Float 80.23M · 90.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.02M | 10.18% | 13F | Aug 7, 2026 |
| Kynam Capital Management, LP | 8.05M | 9.09% | 13F | Aug 14, 2026 |
| Goldman Sachs Group Inc | 5.86M | 6.61% | 13F | Aug 14, 2026 |
| State Street Corporation | 5.66M | 6.40% | 13G | Aug 7, 2026 |
| Bank of America Corp /DE/ | 4.05M | 4.57% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 8, 2026 | Michael A. Metzger | director, officer: Chief Executive Officer | −32,375 | $24.24 |
| Jun 12, 2026 | Nicholas A.J. Botwood | officer: Head of R&D, CMO | −31,235 | $18.14 |
| Jun 11, 2026 | Nicholas A.J. Botwood | officer: Head of R&D, CMO | −34,280 | $18.00 |
| Jun 1, 2026 | Michael A. Metzger | director, officer: Chief Executive Officer | −6,847 | $18.99 |
| Jun 1, 2026 | Keith A. Goldan | officer: Chief Financial Officer | −1,177 | $18.99 |
Peers
- Kura
Second FDA-approved menin inhibitor with same R/R NPM1-mutated AML label
- Sanofi (ADR)
Rezurock holds identical cGVHD label to Niktimvo (≥2 prior lines)
- Incyte
Partner on Niktimvo yet upstream cGVHD competitor via Jakafi
- Bristol-Myers Squibb
Diversified biopharma with hematology franchise spanning AML and GVHD prevention
- Mesoblast (ADR)
First MSC therapy approved for pediatric steroid-refractory acute GVHD
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals | $19.39 | −0.77% | $1.73B | — | — | 6.9 | +91.8% |
| Kura | $12.70 | +0.47% | $1.12B | — | — | 14.6 | +36.5% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Mesoblast (ADR) | $17.44 | −0.17% | $2.26B | — | — | 35.0 | +882.8% |
| Median | 15.8 | 26.7 | 4.3 | +36.5% |